1. Home
  2. MRC vs MLYS Comparison

MRC vs MLYS Comparison

Compare MRC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRC
  • MLYS
  • Stock Information
  • Founded
  • MRC 1921
  • MLYS 2019
  • Country
  • MRC United States
  • MLYS United States
  • Employees
  • MRC N/A
  • MLYS N/A
  • Industry
  • MRC Industrial Machinery/Components
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRC Industrials
  • MLYS Health Care
  • Exchange
  • MRC Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • MRC 1.1B
  • MLYS 890.6M
  • IPO Year
  • MRC 2012
  • MLYS 2023
  • Fundamental
  • Price
  • MRC $15.09
  • MLYS $15.48
  • Analyst Decision
  • MRC Strong Buy
  • MLYS Strong Buy
  • Analyst Count
  • MRC 3
  • MLYS 5
  • Target Price
  • MRC $16.00
  • MLYS $31.00
  • AVG Volume (30 Days)
  • MRC 664.0K
  • MLYS 926.3K
  • Earning Date
  • MRC 08-06-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • MRC N/A
  • MLYS N/A
  • EPS Growth
  • MRC N/A
  • MLYS N/A
  • EPS
  • MRC N/A
  • MLYS N/A
  • Revenue
  • MRC $2,945,000,000.00
  • MLYS N/A
  • Revenue This Year
  • MRC $5.81
  • MLYS N/A
  • Revenue Next Year
  • MRC $5.43
  • MLYS N/A
  • P/E Ratio
  • MRC N/A
  • MLYS N/A
  • Revenue Growth
  • MRC N/A
  • MLYS N/A
  • 52 Week Low
  • MRC $9.23
  • MLYS $8.24
  • 52 Week High
  • MRC $15.59
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • MRC 60.32
  • MLYS 59.94
  • Support Level
  • MRC $14.66
  • MLYS $14.53
  • Resistance Level
  • MRC $15.08
  • MLYS $15.79
  • Average True Range (ATR)
  • MRC 0.37
  • MLYS 0.89
  • MACD
  • MRC 0.11
  • MLYS 0.14
  • Stochastic Oscillator
  • MRC 81.01
  • MLYS 90.31

About MRC MRC Global Inc.

MRC Global Inc distributes pipes, valves, fittings, and other infrastructure products and services to diversified gas utility, energy, and industrial end-markets. It provides supply chain solutions, technical product service and a digital platform for customers globally. It offers a range of PVF, oilfield supply, valve automation and modification, measurement, instrumentation, and other general and specialty products. Its geographical segments include the United States and International. It generates the majority of its revenue from the United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: